China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues jumped 294.79% year-on-year (YOY) to RMB360.4 million ($49.67 million). Net loss attributable to the parent company was RMB856.77 million ($118 million), down RMB250.94 million ($34.6 million) from 2023.
Key Highlights
- First Full Sales Year: 2024 marked Dizal’s first year generating product sales, with golidocitinib approved in China in June. The drug is the only JAK1 selective inhibitor for relapsed/refractory peripheral T-cell lymphoma (PTCL) globally.
- NRDL Inclusion: Golidocitinib and sunvozertinib (an EGFR inhibitor) were added to China’s National Reimbursement Drug List (NRDL) in 2024.
- Sunvozertinib US Filing: A market filing for sunvozertinib was accepted by the FDA in January 2025 for priority review, targeting advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.-Fineline Info & Tech
Leave a Reply